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ABSTRACT 
The dynamic nature of membrane along with an uneven distribution of lipids leads to the 
formation of specialized membrane domains where proteins can selectively be included or 
excluded. In this regard, the dynamic and preferential clustering and packing of 
sphingolipids and cholesterol into moving platforms, named as lipid rafts, form membrane 
domains that act as scaffolds for the attachment of specific proteins and for the proper 
functioning of a number of signaling cascades. Lipid rafts harbor several signaling routes 
that promote cell survival and proliferation, and thereby they could play a role in the 
development of cancer. On the other hand, evidences in the last decade have shown that 
lipid rafts can also serve as organizing centers for the assembly of apoptotic and signaling 
molecules involved in cell death, thus opening a new avenue in cancer therapy. Recruitment 
of death receptors and downstream apoptotic signaling molecules in aggregated lipid rafts 
has led to the emerging concept of a plasma membrane platform designated as “cluster of 
apoptotic signaling molecule-enriched rafts” (CASMER) that may play a role in the 
regulation of apoptosis. In addition, lipid rafts also play a major role in neurotoxicity, 
including the production and aggregation of amyloid-β peptide (Aβ) to form neurotoxic Aβ 
oligomers in the brain, which are widely believed to drive Alzheimer’s disease pathology. 
Alterations in cholesterol have been detected in cell models for cancer and 
neurodegenerative diseases, which might lead to changes in cholesterol-rich rafts and 
thereby in the regulation of cell death or survival. However, it is currently unclear what the 
potential mechanisms underlying cholesterol perturbations are. Growing evidence suggests 
that compartmentalization of macrocomplexes and signaling routes in lipid rafts has a 
crucial role in the regulation of cell fate, being of major importance in different pathologies, 
including cancer and neurodegenerative diseases. Despite the underlying mechanisms and 
functional impact of protein compartmentalization are still not well understood, the 
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modulation of lipid rafts opens new approaches in the treatment of these diseases for which 
current available therapies are not satisfactory. 
INTRODUCTION 
The role of apoptosis in normal physiology is as significant as that of its counterpart, 
mitosis, in the regulation of cell populations. In adulthood, about 10 billion cells die every 
day simply to keep balance with the numbers of new cells arising from the body’s stem cell 
populations (1). This normal homeostasis is tightly regulated through apoptosis. 
Abnormalities in cell death regulation can be a significant component of serious diseases, 
such as cancer, associated with deficient apoptosis, and neurodegenerative disorders, 
associated with excessive apoptosis. In this regard, emerging evidence suggests that insight 
in how cells handle cholesterol seems to be of major importance for keeping the number of 
cell populations constant within narrow limits, and breakdown of cholesterol homeostasis 
may cause several disease states (2). Despite cholesterol accumulation in tumors was first 
reported in the early 20
th
 century (3-5), its role in cancer development remains to be 
elucidated. Subsequent reports also supported a higher cholesterol content in tumor cells 
than in their normal counterparts, and there is now increasing evidence to suggest a link 
between cholesterol accumulation and the risk of certain malignancies (6-10). Several 
epidemiologic studies have described a reduced incidence of certain cancers in patients 
taking 3-hydroxy-3-methyl-glutaryl CoA (HMG-CoA) reductase inhibitors (“statins”) for 
cardiovascular indications (11-16), which inhibit the rate-limiting step of conversion of 
HMG-CoA to mevalonate in cholesterol biosynthesis.  
In addition, evidence has accumulated for the last 2 decades in support of the 
hypothesis that elevated cholesterol levels increase the risk of developing Alzheimer’s 
disease (AD) (17,18). The brain is particularly enriched in cholesterol, which is essential for 
neuronal development and survival, maintenance of membrane integrity in neurons, synapse 
maturation, and optimal synaptic activity. About 23-25 percent of the body's total 
cholesterol level is found in the central nervous system (19), and alterations in brain 
cholesterol homeostasis are linked to neurodegeneration. Recent findings suggest that 
alterations in cholesterol homeostasis are associated with several neurodegenerative 
disorders, including Huntington’s disease and AD (20-23). 
The advent of the concept of lipid rafts in 1997 (24), as membrane domains enriched 
in cholesterol and sphingolipids, has changed dramatically our vision of the role of 
cholesterol in cell function. Lipid rafts are membrane microdomains of reduced fluidity 
consisting of dynamic assemblies of cholesterol and sphingolipids (25,26). The presence of 
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saturated hydrocarbon chains in sphingolipids allows for cholesterol to be tightly 
intercalated, leading to the presence of distinct liquid-ordered phases, i.e. membrane rafts, 
dispersed in the liquid-disordered matrix, and thereby more fluid lipid bilayer. Thus, lipid 
rafts are more ordered and tightly packed membrane domains than the surrounding bilayer 
(27,28). The hydrophobic chains of lipids in the rafts are more saturated and tightly packed 
than the surrounding bilayer. Cholesterol is the dynamic glue that holds the raft together and 
influences lipid-protein interactions by increasing the thickness of the lipid bilayer. One of 
the most important features of lipid rafts is that they can include or exclude proteins. On 
these grounds, these dynamic specialized membrane raft microdomains of reduced fluidity 
may serve as foci for recruitment of distinct molecules at the plasma membrane (25,26,29), 
thus playing a major role in the compartmentalization of cellular processes, including signal 
transduction and membrane protein trafficking  (25,30). 
LIPID RAFTS IN CANCER DEVELOPMENT 
Lipid rafts form platforms for individual receptors activated by ligand binding. This 
activation could lead to the recruitment in the membrane raft of appropriate signaling 
molecules, and signal transmission could be protected from non-raft enzymes, such as 
membrane phosphatases, that otherwise could affect the signaling process. Thus, raft binding 
recruits proteins to a new microenvironment, where the phosphorylation state of proteins can 
be modified by local kinases and phosphatases, resulting in downstream signaling (25). On 
these grounds, recruitment, retention and exclusion of certain proteins in lipid rafts leads to 
identify these membrane domains as privileged sites where the interaction between discrete 
subsets of signaling molecules is highly favored, thereby serving as platforms for signal 
transduction (25). Thus, spatial compartmentalization of signaling pathway components 
generally defines the specificity and enhances the efficiency of signal transduction. A wide 
number of signal transduction process have been reported to occur in lipid rafts, including 
those related to immune system (T-cell receptor, B-cell receptor, FcεRI receptor) and cell 
survival and proliferation (insulin receptor, H-Ras, EGF receptor) (25). 
Interestingly, cholesterol-rich rafts mediate Akt signaling in cancer cells (5,10). 
Activated phosphatidylinositol 3-kinase (PI3K) and its downstream target Akt/PKB are 
important signaling molecules and key survival factors involved in the control of cell 
proliferation, apoptosis and oncogenesis. Aberrant activation of PI3K-Akt pathway may 
contribute to the development and invasiveness of cancer cells (31,32). Thus, because PI3K-
Akt pathway is compartmentalized within plasma membrane raft domains (33), as well as 
some additional survival signaling pathways, these membrane domains may play a role in 
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cancer progression (34). Furthermore, lipid rafts play a crucial role in the localization and 
functionality of CD44, which regulates cancer cell adhesion and migration (35). 
Interestingy, treatment of human glioma cells with the lipid raft disrupting agent methyl-β-
cyclodextrin led to an increase in CD44 (35). Thus, low cholesterol triggers raft-dependent 
CD44 shedding and suppresses tumor cells migration (35). The cholesterol-lowering 
medication symvastatin has also been reported to enhance CD44 shedding, and to block the 
stimulation of glioma cell migration by hyaluronan oligosaccharides or epidermal growth 
factor (36-39). Thus, these results suggest that lowering cholesterol levels may disturb the 
regulated CD44 membrane localization in rafts that is necessary for enhanced cancer cell 
adhesion and migration (39). Unlike CD44, which was present in lipid rafts, its processing 
enzyme, a disintegrin and metalloproteinase 10 (ADAM10), was largely in non-raft fractions 
(35). Displacement of CD44 from lipid raft to non-raft membrane domains, where ADAM10 
is located, might make CD44 accessible to ADAM10 and thereby to CD44 shedding (39). 
An increasing number of proteins involved in the development of several malignant cancers 
are being detected to be associated with lipid rafts (40), such as the type 1 transmembrane 
glycoprotein mucin 1 (MUC1) (41) and urokinase plasminogen activator receptor (uPAR) 
(42), suggesting  major role of lipid rafts in tumor progression. In this regard, the cholesterol 
content in tumor cells has been reported to be higher than in normal cells (6-9,43). Likewise, 
cancer cells have been suggested to display higher levels of cholesterol-rich lipid rafts than 
their normal counterparts (44).  
 
LIPID RAFTS IN CANCER CHEMOTHERAPY 
While investigating the mechanism of action of the antitumor ether phospholipid edelfosine  
1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-18-OCH3), the prototype of a 
heterogenous family of compounds collectively known as synthetic alkyl-lysophospholipid 
analogues (ALPs) or antitumor lipids (ATLs) (45,46), we found in 2000 that the induction of 
apoptosis triggered by this drug in leukemic cells was dependent on the death receptor 
Fas/CD95, which resulted aggregated at one pole of the cell to form caps on the cell surface 
(47). Soon afterwards in 2001, we found out that edelfosine prompted translocation and co-
clustering of the death receptor Fas/CD95 into membrane rafts, thus uncovering a new 
molecular process in the regulation of apoptosis through membrane rafts (48). This new 
mechanism of action involved for the first time membrane rafts in Fas/CD95-mediated 
apoptosis and cancer chemotherapy (48). Confocal microscopy analyses (Figure 1) and 
isolation of membrane rafts through sucrose gradient centrifugation showed co-aggregation 
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of Fas/CD95 and lipid rafts after incubation of Jurkat T-cell leukemia cells with edelfosine. 
Raft disruption, following treatment with the cholesterol-depleting agent methyl- -
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lfosine-induced Fas/CD95 clustering and apoptosis (48). These results showed that lipid 
rafts could not only harbor molecules related to survival and proliferating signaling, as 
mentioned above, but also cell death signaling molecules, such as death receptor Fas/CD95. 
Subsequent evidences showed that that Fas/CD95 was also translocated into lipid 
rafts following activation with its natural ligand FasL/CD95L (49,50). On these grounds, 
edelfosine mimicked to some extent the action of the natural ligand FasL/CD95L on 
promoting death receptor clustering in lipid rafts. However, translocation of Fas/CD95 into 
membrane rafts following edelfosine treatment was independent of receptor interaction with 
FasL/CD95L (47,48). Furthermore, Fas/CD95 was triggered intracellularly by edelfosine, so 
the drug was acting from within the cell independently of FasL/CD95L (51). Thus, these 
data indicate that Fas/CD95 aggregation in rafts and its ensuing activation can be modulated 
pharmacologically.  
Additional studies have shown that edelfosine not only induced recruitment of the 
death receptor Fas/CD95 in lipid rafts, but also promoted translocation of downstream 
signaling molecules into rafts. Fas-associated death domain protein (FADD) and procaspase-
8, which together with Fas/CD95 form the death inducing signaling complex (DISC), 
required to mount an apoptosis signal, were also recruited into membrane rafts upon 
edelfosine treatment in a number of hematopoietic cancer cells (51-53). Formation of DISC 
was visualized upon edelfosine treatment by electron microscopy (Figure 2) and co-
immunoprecipitation assays (52,53). A number of additional antitumor drugs have been 
recently reported to promote the recruitment of the three major constituents of DISC, namely 
Fas/CD95, FADD and procaspase-8, into lipid rafts, including  perifosine (52), cis-platin 
(54), resveratrol (55,56), aplidin (57), rituximab (58), and avicin D (59). 
Aggregation of death receptors in a rather small area of the cell, such as lipid raft 
membrane domains, following antitumor chemotherapy, would allow a potent synergy with 
death receptor ligands to achieve cell death. On these grounds, a number of antitumor drugs, 
including resveratrol (56,60), aplidin (57), edelfosine (52) and perifosine (52) have been 
reported to recruit death receptors Fas/CD95, tumor necrosis factor receptor 1 (TNFR1) and 
TNF-related apoptosis-inducing ligand (TRAIL) receptors, named death receptor (DR) 4 and 
DR5, into lipid rafts, and this protein redistribution sensitized the cells to death receptor 
stimulation by their cognate ligands or agonistic cytotoxic antibodies (52,60). The above DISC 
apoptotic complex can also be formed with the death receptors DR4 and DR5(61-63), and these 
TRAIL receptor-mediated DISCs are also suggested to be recruited into rafts following 
treatment with a number of antitumor drugs (52,56,60). 
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 Interestingly, some anticancer drugs, including edelfosine (51,64), perifosine (65) and 
aplidin (57), have been reported to accumulate in lipid rafts and to reorganize these 
membrane domains, affecting their protein composition. Thus, these data indicate that lipid 
rafts can be targeted by chemical compounds, leading to a new way to regulate cell fate, 
either promoting apoptosis or survival.    
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APOPTOTIC SIGNALING MOLECULES IN LIPID RAFTS 
In addition to DISC constituents, an increasing number of proteins involved in cell death 
regulation are being reported to be accumulated in membrane rafts upon treatment of cancer 
cells with antitumor drugs. In this regard, downstream apoptotic signaling molecules, 
including procaspase-10, c-Jun N-terminal kinase (JNK), and BH3-interacting domain death 
agonist (Bid) have been found to be translocated into membrane rafts of cancer cells 
following edelfosine treatment (51,52,66,67). Persistent JNK activation is associated with 
apoptosis (68,69), and Bid acts as a connector between Fas/CD95-mediated extrinsic 
signaling and the mitochondrial-dependent intrinsic pathway of apoptosis (70). The 
antitumor drugs aplidin (57) and resveratrol (56) also induce recruitment of JNK and Bid in 
membrane rafts in human leukemic cells. This may explain the dependence of edelfosine-, 
aplidin- and resveratrol-mediated apoptosis on both JNK and mitochondrial signaling 
(56,69,71,72). Redistribution of death receptors and downstream signaling molecules into 
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lipid rafts does not require protein synthesis, and therefore it is achieved from the pre-
existing protein pool (51).  
 
THE CONCEPT OF CASMER IN THE REGULATION OF APOPTOSIS 
Recruitment of death receptors and downstream signaling molecules in lipid rafts is 
expected to facilitate and potentiate protein-protein interactions and cross-talk between 
different signaling pathways, which could eventually lead to the triggering of cell death 
signals. The outstanding recruitment of death receptors, together with downstream apoptotic 
signaling molecules, in aggregated rafts has led us to coin the word CASMER as an 
acronym of “cluster of apoptotic signaling molecule-enriched rafts” (57,67,73,74). 
CASMER refers to the recruitment of death receptors together with downstream apoptotic 
signaling molecules in aggregated rafts (73,74). CASMER represents a novel raft-based 
supramolecular entity, acting as death-promoting platforms where death receptors and 
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ng molecules are brought together (Figure 3). Thus, CASMER formation would facilitate 
protein-protein interactions and the transmission of apoptotic signals. The efficiency in 
promoting CASMER formation, as well as CASMER protein composition, would depend on 
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the cell phenotype and the triggering stimulus (73,74). A basic protein composition of 
CASMER would include the recruitment of death receptors in aggregated rafts (73,74), but 
CASMERs could increase in complexity by recruiting additional downstream signaling 
molecules in lipid rafts, including DISC components FADD and procaspase-8, Bid, and JNK 
(52,53,73-75). The higher number of proteins recruited in CASMERs, the more efficient the 
apoptosis response launched. CASMER formation seems to play an important role in cross-
talk processes occurring during apoptosis. In this regard, the recruitment of Bid in 
membrane rafts highlights a major role of rafts as a putative connector between extrinsic and 
intrinsic signaling pathways in apoptosis (51,52,56,57,67).  
 
LIPID RAFTS IN NEURODEGENERATIVE DISEASES 
A growing amount of evidence suggests a mechanistic link between cholesterol metabolism 
in the brain and the formation of amyloid plaques in AD development (76). In addition, 
recent evidence suggests that ganglioside GM1, another component of rafts, facilitates the 
binding and accumulation of Aβ oligomers at lipid rafts (77,78). Lipid rafts play a number of 
critical roles in AD, namely promoting the generation of the amyloid-β peptide (Aβ), 
facilitating its aggregation upon neuronal membranes to form toxic oligomers and hosting 
neuronal receptors through which AD-related neurotoxicity of the Aβ oligomers is 
transduced (79). Neuronal sensitivity to Aβ–induced toxicity has been found to be dependent 
upon Aβ binding to the cell membrane (80). Soluble Aβ dimers accumulate rapidly, and 
have been found at elevated levels, in lipid rafts from human and transgenic mouse model 
mouse AD brains (81), as well as in presynaptic terminals in cholesterol- and ganglioside 
GM1-rich lipid rafts from AD cortex (82). Cholesterol modulates the interaction of the Aβ 
peptide with lipid bilayers (83). Aβ oligomers isolated from AD patients associate with lipid 
rafts in a cholesterol-dependent way, and cholesterol depletion decreases Aβ aggregation 
(84). Additional studies have revealed that an increase in the level of cholesterol in human 
neuroblastoma cells reduces Aβ oligomer binding (85,86), suggesting that a fluctuation in 
cholesterol levels may alter the physical properties of lipid rafts thereby modulating Aβ 
oligomer binding (86). Cholesterol and statins clearly modulate β-amyloid precursor protein 
processing in cell culture and animal models (76). In addition, Aβ oligomer binding induces 
the clustering of neuronal receptors into aberrant pathogenic signaling platforms (87), and 
thereby lipid rafts may represent platforms for Aβ oligomer-mediated neurotoxicity (79). 
Lipid rafts can also play a key role in a range of neurodegenerative disease, in addition to 
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AD, including Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and 
prion disease (88). 
Platelet-activating factor (1-O-hexadecyl-2-acetyl-sn-glycerophosphocholine, PAF) 
has been implicated in the neuronal damage that accompanies ischemia, prion disease and 
AD. PAF is elevated in the brains of AD patients and in human neurons exposed to Aβ (89), 
and chronic PAF accumulation leads to an endoplasmic reticulum stress-mediated neuronal 
death (89). Thus, high concentrations of PAF are thought to contribute to neuronal damage. 
On the other hand, studies using PAF antagonists have indicated that PAF is involved in 
neuronal loss in AD (90). The effects of PAF are mediated via a specific receptor (91), 
which is located in neuronal lipid rafts (92). Treatment of neurons with cholesterol synthesis 
inhibitors, including simvastatin and squalestatin, disrupted cholesterol-rich lipid rafts, and 
protected neurons against PAF through a desensitisation of neurons to PAF, likely as a result 
of a displacement of PAF receptors to non-raft membranes (92). 
 
CONCLUSIONS 
Recent advances in our understanding of the organization, composition and function of lipid 
rafts in cancer cells have led to the conclusion that these membrane domains act as platforms 
for the recruitment of signaling processes that regulate cell fate, promoting either survival or 
cell death. Lipid rafts harbor a wide number of signaling cascades involved in survival and 
cell proliferation, thus potentiating cancer development. In this regard, elevated levels of 
cholesterol and lipid rafts have been reported in cancer cells as compared to their normal 
counterparts. However, in the last years increasing evidence has been accumulated for an 
important role of lipid rafts in cell death, acting as scaffolds for death signaling pathways 
and death-promoting processes. The finding that some drugs can accumulate in lipid rafts, 
modulating their protein composition and function, opens exciting new avenues of research 
to get insight into the regulation of cell death in important human pathologies, such as 
cancer and neurodegenerative diseases. A better understanding of how lipid rafts modulate 
cell fate, and how these membrane domains can be modulated, would lead to a significant 
advance in the design of novel strategies in the treatment of cancer and neurodegenerative 
diseases.       
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